Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Introduction: Terminal heart failure is often associated with end-stage kidney disease. Due to advantages concerning patient independence, peritoneal dialysis (PD) is an alternative to conventional hemodialysis treatment. As left ventricular assist device implantations continuously increase, data on combined PD and LVAD is rare. We present the first and largest cohort study on this exclusive patient cohort.

Methods: A retrospective study was conducted on patients who underwent LVAD implantation at a high-volume heart failure center from 2000 to 2024. Adverse events were analyzed according to the INTERMACS classification.

Results: A total of nine patients were identified as undergoing PD on LVAD therapy. Mean age at the time of LVAD implantation was 67 years. Main cause of kidney disease was cardio-renal syndrome (67%). In all patients, PD therapy was established before LVAD implantation. Mean time on PD before LVAD implantation was 72 months. None of the patients were weaned from dialysis nor were converted to conventional dialysis. Four patients experienced driveline infection. Three patients suffered an infection of their PD catheter. A combination of PD and DL infection was detected in two cases. None of these infections were associated with the same pathogens. Mean survival after LVAD + PD was 56.5 months.

Conclusion: Peritoneal dialysis has advantages over hemodialysis including fewer bloodstream infections, fewer hemodynamic shifts, and the comfort of the ambulant setting. This study illustrates that PD in LVAD patients is feasible and long-term support up to several years is achievable without major complications.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12120810PMC
http://dx.doi.org/10.1111/aor.14970DOI Listing

Publication Analysis

Top Keywords

lvad implantation
16
peritoneal dialysis
12
patients
8
dialysis patients
8
left ventricular
8
ventricular assist
8
assist device
8
heart failure
8
kidney disease
8
time lvad
8

Similar Publications

Introduction: Left ventricular assist device (LVAD) implantation is a highly effective procedure for the management of selected advanced heart failure patients, prolonging patient life and improving quality. Additional cardiac pathologies, especially valvular regurgitation or coronary heart disease, are common in LVAD recipients, whereas reports on the surgical management of heart failure combined with aortic disease are rare.

Case Presentation: We present a case of a 60-year-old patient with an aortic sinus aneurysm, aortic regurgitation, and end-stage heart failure.

View Article and Find Full Text PDF

Long Term Outcomes of Tricuspid Valve Repair or Replacement in Patients with Continuous Flow Left Ventricular Assist Devices.

J Thorac Cardiovasc Surg

September 2025

Division of Cardiac, Thoracic & Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, NY. Electronic address:

Objective: Our objective was to determine the long-term outcomes of concomitant tricuspid valve procedures (TVP) during continuous-flow left ventricular assist device (LVAD) implantation.

Methods: We retrospectively reviewed patients who received HeartMate II or 3 from 2004 to 2023. Nine patients who had a previous TVP were excluded.

View Article and Find Full Text PDF

Left ventricular assist device (LVAD) explantation is technically challenging during heart transplantation (HT) and is associated with intraoperative and postoperative blood loss. This single institution study examined the effects of partial polytetrafluoroethylene (PTFE) protective coverage during HeartMate 3 implant on perioperative blood loss during the explant-HT. We found that partial PTFE coverage of the outflow graft and chassis during HeartMate 3 implant is significantly associated with reduced intraoperative and postoperative transfusion requirements, and postoperative chest tube output.

View Article and Find Full Text PDF

Strategic Approach Towards the Evaluation of HeartMate 3 Left Ventricular Assist Devices Using Multimodality Imaging.

Am J Cardiol

August 2025

Division of Cardiovascular Diseases and Hypertension, Rutgers University - Robert Wood Johnson Medical School, 125 Paterson Street, East Tower - 8th Floor, New Brunswick, New Jersey 08901, United States. Electronic address:

The use of left ventricular assist devices (LVADs) has increased in recent years as a destination therapy. The HeartMate 3 (HM3) is currently the only commercially available LVAD for implantation in the United States. Societal guidelines for multimodality cardiac imaging evaluation of LVADs and temporary mechanical support devices were recently published and serve as a comprehensive resource for the evaluation of LVAD patients.

View Article and Find Full Text PDF

Impact of pump position on postoperative outcomes in less invasive left ventricular assist device implantation.

Front Cardiovasc Med

August 2025

Department of Cardiac Surgery and Research Group for Experimental Surgery, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany.

Introduction: less invasive approach (LIS) has recently become increasingly used for left ventricular assist device (LVAD) implantation. However, the impact of surgical access on pump position and clinical outcomes comparing LIS-LVAD implantation to full sternotomy (ST) has not been well discussed.

Methods: Between April 2010 and February 2021, a total of 237 consecutive patients received a LVAD, 76 (32.

View Article and Find Full Text PDF